An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use (ENBRECAP2009)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2010 by Florida Academic Dermatology Centers.
Recruitment status was Recruiting
Information provided by:
Florida Academic Dermatology Centers
First received: May 25, 2010
Last updated: May 27, 2010
Last verified: May 2010
The purpose of this study is to evaluate the efficacy of re-treatment with etanercept 50mg subcutaneous injections twice weekly for 12 weeks in subjects who have previously been treated etanercept and efficacy diminished.
||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use
Primary Outcome Measures:
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||December 2010 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Subjects with psoriasis who have previously been treated with etanercept for a minimum of 6 months and discontinued treatment due to loss of efficacy. Every attempt will be made to obtain loss of efficacy history from the subject's medical chart;when etanercept was commenced and terminated and description of patient's psoriasis on termination and details of new treatment commenced. Subjects must have failed their latest psoriasis treatment after a period of three months. This will be measured as a PGA of ≥ 3.
- There is no specific requirement as to when prior treatment with etanercept occurred and no requirement as to what type of treatment(s) used between initial and subsequent treatments.
- Are ≥ 18 years of age
- PGA ≥ 3
- BSA minimum of 5%
Tuberculosis inclusion criteria
- Current enrollment in any other investigational device or investigational drug trial(s), or receipt of any other investigational agent(s) within 28 days before baseline visit.
- Known hypersensitivity to Enbrel® (etanercept) or any of its components or known to have antibodies to etanercept.
- Latex sensitivity [NB: only applicable if they are using prefilled syringe or prefilled SureClick™ autoinjector presentations]
- Prior or concurrent use of cyclophosphamide therapy
- Concurrent sulfasalazine therapy.
- A positive HBV test or known history of any other immuno-suppressing disease.
- Any mycobacterial disease or high risk factors for tuberculosis (TB), such as family member with TB, positive purified protein derivative (PPD) or taking anti-tuberculosis medication.
- Active or chronic infection within 4 weeks before screening visit, or between the screening and baseline visits.
- History of listeriosis, histoplasmosis, chronic or active Hepatitis B infection and Hepatitis C, human immunodeficiency virus (HIV) infection, immunodeficiency syndrome, chronic recurring infections or active TB, or other opportunistic infections
- If etanercept was previously discontinued due to a serious adverse event
- Severe comorbidities (diabetes mellitus requiring insulin; CHF of any severity; or myocardial infarction, cerebrovascular accident or transient ischemic attack within 6 months of screening visit; unstable angina pectoris; uncontrolled hypertension (sitting systolic BP <80 mm Hg or > 160 or diastolic BP > 100 mm Hg); oxygen-dependent severe pulmonary disease; history of cancer within 5 years [other than resected cutaneous basal or squamous cell carcinoma of the skin or in situ cervical cancer])
- Systemic lupus erythematosus, history of multiple sclerosis, transverse myelitis, optic neuritis or seizure disorder.
- Use of a live vaccine 90 days prior to screening visit, or concurrent use of a live vaccine.
- Any condition or circumstances judged by the patient's physician [or the investigator or medically qualified study staff] to render this clinical trial detrimental or otherwise unsuitable for the patient's participation.
- Female subjects who are pregnant, nursing or planning pregnancy (both men and women) and not using acceptable methods of birth control during the trial (hormonal, barriers, abstinence).
- Women who are breast feeding
History of non-compliance with other therapies.
- History of alcohol abuse within the last 12 months
- Concurrent use of anakinra
- Subjects who cannot discontinue any of the drugs below for 2 weeks prior to the baseline visit or during the study;
A two week wash out period is appropriate as it would be unethical to expect subjects whose disease if flaring to remain untreated for a longer period of time. The first dose of etanercept will be administered two weeks after the last biologic dose.
- Immunosuppressants, antimalarials, or sulfasalazine.
- Other Ani-TNFs
- Live vaccines
- Oral retinoids (isotretinoin,acitretin,bexarotene)
- Ultra violet light therapies
Please refer to this study by its ClinicalTrials.gov identifier: NCT01132235
|Florida Academic Dermatology Center
|Miami, Florida, United States, 33136 |
|Contact: Annika M Grant, RN.MBA 305-324-2110 ext 210 firstname.lastname@example.org |
Florida Academic Dermatology Centers
No publications provided
||Francisco A Kerdel, M.D., Florida Academic Dermatology Centers
History of Changes
|Other Study ID Numbers:
|Study First Received:
||May 25, 2010
||May 27, 2010
||United States: Food and Drug Administration
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 16, 2013
Skin Diseases, Papulosquamous
TNFR-Fc fusion protein
Anti-Inflammatory Agents, Non-Steroidal
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Central Nervous System Agents